In Dubai, healthcare professionals, particularly endocrinologists, diabetologists, and internal medicine specialists, hold a favorable and evidence-based opinion of Mounjaro (tirzepatide), recognizing its significant advantages for its approved uses. Their perspectives align with global medical consensus, emphasizing its efficacy when utilized under strict medical supervision.
https://www.glamclinicdubai.ae/en/cosmetic-injectables/mounjaro-injection/
Key Points Highlighted by Doctors in Dubai Regarding Mounjaro:
1. Transformative for Type 2 Diabetes Management:
Dual Mode of Action: Physicians emphasize Mounjaro's unique dual agonism, targeting both Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptors. This dual approach results in more comprehensive blood sugar regulation compared to older medications or GLP-1 agonists alone.
Substantial Reduction in HbA1c: Medical professionals in Dubai attest to Mounjaro's effectiveness in significantly lowering HbA1c levels, aiding patients in achieving improved glycemic control, a primary benefit for individuals with diabetes.
Enhanced Insulin Sensitivity: By promoting insulin release during elevated blood sugar levels and reducing glucose production by the liver, Mounjaro enhances the body's natural response to glucose.
Convenience: The once-weekly injection regimen is seen as a notable advantage for patient compliance, enhancing overall treatment outcomes compared to daily injections.
2. Encouraging Results and Approval for Weight Loss (with specific criteria):
Recognized Efficacy: Healthcare providers in Dubai acknowledge the remarkable weight loss observed in clinical trials (SURMOUNT studies) among individuals using Mounjaro. They explain that it functions by slowing gastric emptying and reducing appetite, leading to increased satiety and reduced food intake.
Dual Benefit for Diabetic Patients: For individuals with Type 2 Diabetes who are overweight or obese, doctors highlight Mounjaro's dual advantage – improving blood sugar levels and promoting significant weight loss, further supporting diabetes management.
Approval for Long-term Weight Management: Many clinics and healthcare professionals confirm that Mounjaro is approved for chronic weight management in non-diabetic adults with obesity (BMI ≥ 30 kg/m²) or those who are overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, hypercholesterolemia, sleep apnea), reflecting a progressive approach to addressing obesity as a medical condition.
Integration into Comprehensive Plans: Doctors emphasize that Mounjaro for weight loss is not a standalone solution. They incorporate it into comprehensive weight management programs that include structured dietary advice (often from a dietitian), regular physical activity, and behavioral modifications. They stress the importance of adhering to these lifestyle changes for optimal and sustained outcomes.
3. Focus on Medical Oversight and Patient Selection:
Strict Prescription Requirement: Doctors in Dubai emphasize that Mounjaro is available only by prescription. They adhere to regulations set by the Dubai Health Authority (DHA) and the Ministry of Health and Prevention (MoHAP), prescribing it only after a thorough medical evaluation.
Comprehensive Patient Assessment: Prior to prescribing, physicians conduct thorough evaluations, including:
- Reviewing complete medical history (including family history of thyroid cancer and MEN 2, and personal history of pancreatitis or severe gastrointestinal issues).
- Physical examination.
- Relevant laboratory tests (e.g., blood sugar, kidney function, liver function).
- Evaluation of current medications to identify potential interactions (e.g., oral contraceptives).
Contraindications: Healthcare professionals in Dubai exercise caution when prescribing Mounjaro to individuals with:
- Type 1 Diabetes (as it is not approved for this condition).
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- History of pancreatitis.
- Severe gastrointestinal disorders (e.g., gastroparesis).
- Pregnancy or breastfeeding.
Dosage Adjustment and Monitoring: Physicians carefully guide patients through the dosage titration process (starting with a low dose and gradually increasing) to minimize side effects and optimize treatment. Regular follow-up appointments are crucial for monitoring effectiveness, managing side effects, and making any necessary adjustments.
4. Awareness of Side Effects and Risks:
Common Side Effects: Doctors openly discuss common gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, and reduced appetite. They provide guidance on managing these symptoms.
Serious but Rare Risks: Patients are informed about rarer but severe risks like pancreatitis, gallbladder issues, severe hypoglycemia (especially when combined with other diabetes medications), and the theoretical risk of thyroid C-cell tumors (based on animal studies). Patients are educated on warning signs and when to seek immediate medical attention.
Encouraging Reporting: Patients are encouraged to promptly report any unusual or severe symptoms.
5. Addressing Supply Challenges and Misuse Concerns:
Supply Constraints: Healthcare providers acknowledge that the high global demand for Mounjaro (and similar medications